Abstract:Background Cardiac remodeling predisposes individuals to heart failure if the burden is not solved, and heart failure is a growing cause of morbidity and mortality worldwide. The cardiac extracellular matrix not only provides structural support, but also is a core aspect of the myocardial response to various biomechanical stresses and heart failure. MFAP4 (microfibrillar‐associated protein 4) is an integrin ligand located in the extracellular matrix, whose biological functions in the heart remain poorly understood. In the current study we aimed to test the role of MFAP4 in cardiac remodeling. Methods and Results MFAP4‐deficient (MFAP4 −/− ) and wild‐type mice were subjected to aortic banding surgery and isoproterenol to establish models of cardiac remodeling. We also evaluated the functional effects of MFAP4 on cardiac hypertrophy, fibrosis, and cardiac electrical remodeling. The expression of MFAP4 was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. After challenge of 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol, MFAP4 −/− mice exhibited lower levels of cardiac fibrosis and fewer ventricular arrhythmias than wild‐type mice. However, there was no significant effect on cardiomyocyte hypertrophy. In addition, there was no significant difference in cardiac fibrosis severity, hypertrophy, or ventricular arrhythmia incidence between wild‐type‐sham and knockout‐sham mice. Conclusions These findings are the first to demonstrate that MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. In addition, MFAP4 deficiency had no significant effect on cardiac fibrosis, hypertrophy, or ventricular arrhythmia in the sham group in this study. Nonstandard Abbreviations and Acronyms AB aortic banding Ad‐shMFAP4 pDKD‐CMV‐eGFP‐U6‐shRNA‐MFAP4 Ad‐shRNA pDKD‐CMV‐eGFP‐U6‐shRNA PCL pacing cycle length MFAP4 microfibrillar‐associated protein 4 VA ventricular arrhythmias Ad‐MFAP4 Adenovirus vector pAdeno‐EF1A(S)‐mNeonGreen‐CMVMfap4‐3FLAG Clinical Perspective What Is New? For the first time we have defined the expression of MFAP4 (microfibrillar‐associated protein 4) was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. What Are the Clinical Implications? MFAP4 may act as a novel therapeutic target for the upstream prevention of cardiac remodeling and heart failure. Heart failure (HF) is the common ultimate outcome of different types of cardiovascular diseases, and is a growing public health problem associated with high hospitalization and mortality. 1 , 2 , 3 , 4 Cardiac remodeling is an adaptive cellular response to various kinds of biomechanical stresses or hemodynamic overload, that involves a series of structural and functional alterations, including increase in the size and/or thickness of cardiomyocytes and the left ventricle, perivascular and interstitial fibrosis, various types of ventricular and atrial arrhythmias and so on. 5 , 6 Cardiac remodeling predisposes a patient to HF if the burden is not solved, and can be divided into structural remodeling and electrical remodeling. Structural remodeling includes cardiac fibrosis and cardiac hypertroph -Abstract Truncated-

Microfibrillar-associated protein 4 in health and disease

MFAP4-Mediated Effects in Elastic Fiber Homeostasis, Integrin Signaling and Cancer, and Its Role in Teleost Fish

Microfibril-associated glycoprotein 4 forms octamers that mediate interactions with elastogenic proteins and cells

Site‐specific absence of microfibrillar‐associated protein 4 (MFAP4) from the internal elastic membrane of arterioles in the rheumatoid arthritis synovial membrane: an immunohistochemical study in patients with advanced rheumatoid arthritis versus osteoarthritis

Integrated Analysis of Microfibrillar-Associated Proteins Reveals MFAP4 As a Novel Biomarker in Human Cancers

Deletion of Microfibrillar-Associated Protein 4 Attenuates Left Ventricular Remodeling and Dysfunction in Heart Failure.

MFAP4 Deficiency Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Through Regulation of Macrophage Infiltration and Activity

MFAP4 deficiency alleviates renal fibrosis through inhibition of NF‐κB and TGF‐β/Smad signaling pathways

Microfibril-associated glycoprotein 4 (Mfap4) regulates haematopoiesis in zebrafish

MFAP4 Promotes Vascular Smooth Muscle Migration, Proliferation and Accelerates Neointima Formation

MMP Mediated Degradation of Type IV Collagen Alpha 1 and Alpha 3 Chains Reflects Basement Membrane Remodeling in Experimental and Clinical Fibrosis – Validation of Two Novel Biomarker Assays

Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D

MFAP4-Deficiency Aggravates Age-Induced Changes in Resistance Artery Structure, While Ameliorating Hypertension

S100A4 a classical DAMP as a therapeutic target in fibrosis

Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients

We-W37:6 Deficiency of Macrophage Phospholipid Transfer Protein Protects Against Atherosclerotic Lesion Development

Tumor-suppressive Role of Microfibrillar Associated Protein 4 and Its Clinical Significance As Prognostic Factor and Diagnostic Biomarker in Hepatocellular Carcinoma.

Fibroblast activation protein in liver fibrosis.

Focus on TRPV4 and Collagen

Fibroblast activation protein and chronic liver disease.

Microfibril-Associated Protein-3-Like Regulates TGF β -Induced EMT Process via TNFR2/p38 MAPK Pathway in Endothelial Cells